The role of central nervous system development in late-onset neurodegenerative disorders

Developmental Neuroscience

Volumn 34, Issue 2-3, 2012, Pages 129-139

  Palubinsky, Amy M ^a,b,c   Martin, Jacob A ^b,c,d   McLaughlin, Beth Ann ^b,c,e,f  

^a Neurosciences Graduate Program   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d Departments of Neurological Surgery   (United States)

^e Departments of Neurology   (United States)

^f VANDERBILT UNIVERSITY   (United States)

Author keywords

Mitochondria; Neural development; Neurodegeneration; Oxidative stress; Parkinson's disease; Programmed cell death; Reactive oxygen species; Stress sensors

Indexed keywords

ADENOSINE TRIPHOSPHATE; NEUROTROPHIN; PARKIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; REACTIVE OXYGEN METABOLITE;

AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; ARTICLE; CELL FATE; CELL PROLIFERATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; ENVIRONMENTAL STRESS; GENE; HUMAN; MITOCHONDRION; MITOPHAGY; MOLECULAR STABILITY; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; ONSET AGE; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

BRAIN; CELL DEATH; HUMANS; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES; NEURONS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84866287634     PISSN: 03785866     EISSN: 14219859     Source Type: Journal    
DOI: 10.1159/000336828     Document Type: Article

References (71)

1. Levitt P, Ebert P, Mirnics K, Nimgaonkar VL, Lewis DA, Making the case for a candidate vulnerability gene in schizophrenia: Convergent evidence for regulator of g-protein signaling 4 (RGS4). Biol Psychiatry 2006; 60: 534-537.
2. Faludi G, Mirnics K: Synaptic changes in the brain of subjects with schizophrenia. Int J Dev Neurosci 2011; 29: 305-309.
3. Raedler TJ, Knable MB, Weinberger DR: Schizophrenia as a developmental disorder of the cerebral cortex. Curr Opin Neurobiol 1998; 8: 157-161.
4. Berretta S: Extracellular matrix abnormalities in schizophrenia. Neuropharmacology 2011.
5. Schmitt A, Hasan A, Gruber O, Falkai P: Schizophrenia as a disorder of disconnectivity. Eur Arch Psychiatry Clin Neurosci 2011; 261(Suppl 2):S150-S154.
6. Courchesne E, Mouton PR, Calhoun ME, Semendeferi K, Ahrens-Barbeau C, Hallet MJ, Barnes CC, Pierce K: Neuron number and size in prefrontal cortex of children with autism. JAMA 2011; 306: 2001-2010.
7. Courchesne E, Karns CM, Davis HR, Ziccardi R, Carper RA, Tigue ZD, Chisum HJ, Moses P, Pierce K, Lord C, Lincoln AJ, Pizzo S, Schreibman L, Haas RH, Akshoomoff NA, Courchesne RY: Unusual brain growth patterns in early life in patients with autistic disorder. Neurology 2001; 57: 245-254.
8. Oppenheim RW: Cell death during development of the nervous system. Annu Rev Neurosci 1991; 14: 453-501.
9. Huttenlocher PR, Dabholkar AS: Regional differences in synaptogenesis in human cerebral cortex. J Comp Neurol 1997; 387: 167- 178.
10. Chan WY, Lorke DE, Tiu SC, Yew DT: Proliferation and apoptosis in the developing human neocortex. Anat Rec 2002; 267: 261- 276.
11. Oppenheim R, Milligan C: Programmed cell death; in Larry RS (ed): Encyclopedia of Neuroscience. Oxford, Academic Press, 2009, pp 1117-1124.
12. Huang EJ, Reichardt LF: Neurotrophins: Roles in neuronal development and function. Annu Rev Neurosci 2001; 24: 677-736.
13. Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y, Jacobson MD: Programmed cell death and the control of cell survival: Lessons from the nervous system. Science 1993; 262: 695-700.
14. Park DS, Obeidat A, Giovanni A, Greene LA: Cell cycle regulators in neuronal death evoked by excitotoxic stress: Implications for neurodegeneration and its treatment. Neurobiol Aging 2000; 21: 771-781.
15. Herrup K, Neve R, Ackerman SL, Copani A: Divide and die: Cell cycle events as triggers of nerve cell death. J Neurosci 2004; 24: 9232- 9239.
16. Busser J, Geldmacher DS, Herrup K: Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain. J Neurosci 1998; 18: 2801.
17. Campbell DS, Holt CE: Apoptotic pathway and mapks differentially regulate chemotropic responses of retinal growth cones.Neuron 2003; 37: 939-952.
18. Fujita J, Crane AM, Souza MK, Dejosez M, Kyba M, Flavell RA, Thomson JA, Zwaka TP:Caspase activity mediates the differentiation of embryonic stem cells. Cell Stem Cell 2008;2: 595-601.
19. McLaughlin BA, Hartnett KA, Erhardt JA,Legos JJ, White RF, Barone FC, Aizenman E: Caspase 3 activation is essential for neuroprotectionin ischemic preconditioning. Proc Natl Acad Sci USA 2003; 100: 715-720.
20. McLaughlin BA: The kinder side of killer proteases: Caspase activation contributes to neuroprotection and CNS remodeling. Apoptosis 2004; 9: 111-121.
21. Brown MC, Booth CM: Postnatal development of the adult pattern of motor axon distribution in rat muscle. Nature 1983; 304:741-742.
22. Stoica BA, Faden AI: Cell death mechanisms and modulation in traumatic brain injury. Neurotherapeutics 2010; 7: 3-12.
23. Turner MR, Parton MJ, Leigh PN: Clinical trials in ALS: An overview. Semin Neurol 2001; 21: 167-175.
24. Rangasamy SB, Soderstrom K, Bakay RA, Kordower JH: Neurotrophic factor therapy for Parkinson's disease. Prog Brain Res 2010; 184: 237-264.
25. Brodski C, Vogt Weisenhorn DM, Dechant G: Therapy of neurodegenerative diseases using neurotrophic factors: Cell biological perspective. Exp Rev Neurother 2002; 2: 417-426.
26. Kernie SG, Parada LF: The molecular basis for understanding neurotrophins and their relevance to neurologic disease. Arch Neurol 2000; 57: 654-657.
27. Erecinska M, Cherian S, Silver IA: Energy metabolism in mammalian brain during development. Prog Neurobiol 2004; 73: 397- 445.
28. Erecinska M, Cherian S, Silver IA: Brain developmentand susceptibility to damage; ion levels and movements. Curr Top Dev Biol 2005; 69: 139-186.
29. Fukuda A, Prince DA: Postnatal development of electrogenic sodium-pump activity in rat hippocampal pyramidal neurons. Dev Brain Res 1992; 65: 101-114.
30. Schmidt TA, Larsen JS, Kjeldsen K: Quantificationof rat cerebral cortex Na +, K + - ATPase: Effect of age and potassium depletion.J Neurochem 1992; 59: 2094-2104.
31. Pysh JJ: Mitochondrial changes in rat inferior colliculus during postnatal development: An electron microscopic study. Brain Res 1970; 18: 325-342.
32. Bates TE, Almeida A, Heales SJR, Clark JB: Postnatal development of the complexes of the electron transport chain in isolated rat brain mitochondria. Dev Neurosci 1994; 16:321-327.
33. Iadecola C, Anrather J: The immunology of stroke: from mechanisms to translation. Nat Med 2011; 17: 796-808.
34. Hazell AS: Excitotoxic mechanisms in stroke: An update of concepts and treatment strategies. Neurochem Int 2007; 50: 941-953.
35. Adam-Vizi V, Starkov AA: Calcium and mitochondrial reactive oxygen species generation: How to read the facts. J Alzheimers Dis 2011; 20(suppl 2):S413-S426.
36. O'Rourke B, Cortassa S, Aon MA: Mitochondrial ion channels: Gatekeepers of life and death. Physiology (Bethesda) 2005; 20: 303- 315.
37. Turrens JF, Alexandre A, Lehninger AL: Ubisemiquinone is the electron donor for superoxide formation by complex III of heart mitochondria. Arch Biochem Biophys 1985; 237: 408-414.
38. Stadtman ER: Protein oxidation and aging. Free Radic Res 2006; 40: 1250-1258.
39. Martensson J, Jain A, Stole E, Frayer W, Auld PAM, Meister A: Inhibition of glutathione synthesis in the newborn rat - A model for endogenously produced oxidative stress. Proc Natl Acad Sci USA 1991; 88: 9360-9364.
40. Hazelton GA, Lang CA: Glutathione contents of tissues in the aging mouse. Biochem J 1980; 188: 25-30.
41. Lang CA, Mills BJ, Mastropaolo W, Liu MC: Blood glutathione decreases in chronic diseases. J Lab Clin Med 2000; 135: 402-405.
42. Nanda D, Tolputt J, Collard KJ: Changes in brain glutathione levels during postnatal development in the rat. Brain Res Dev Brain Res 1996; 94: 238-241.
43. McQuillen PS, Ferriero DM: Selective vulnerability in the developing central nervous system. Pediatr Neurol 2004; 30: 227-235.
44. Chan DC: Mitochondria: Dynamic organelles in disease, aging, and development. Cell 2006; 125: 1241-1252.
45. Navarro A, Boveris A: Brain mitochondrial dysfunction in aging, neurodegeneration, and Parkinson's disease. Front Aging Neurosci 2010; 2.
46. Palmer CS, Osellame LD, Stojanovski D, Ryan MT: The regulation of mitochondrial morphology: Intricate mechanisms and dynamic machinery. Cell Signal 2011; 23: 1534- 1545.
47. Zuchner S, Mersiyanova IV, Muglia M, Bissar- Tadmouri N, Rochelle J, Dadali EL, Zappia M, Nelis E, Patitucci A, Senderek J, Parman Y, Evgrafov O, Jonghe PD, Takahashi Y, Tsuji S, Pericak-Vance MA, Quattrone A, Battaloglu E, Polyakov AV, Timmerman V, Schroder JM, Vance JM: Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 2004; 36: 449-451.
48. Matsumine H, Saito M, Shimoda-Matsubayashi S, Tanaka H, Ishikawa A, Nakagawa- Hattori Y, Yokochi M, Kobayashi T, Igarashi S, Takano H, Sanpei K, Koike R, Mori H, Kondo T, Mizutani Y, Schaffer AA, Yamamura Y, Nakamura S, Kuzuhara S, Tsuji S, Mizuno Y: Localization of a gene for an autosomal recessive form of juvenile parkinsonism to chromosome 6q25.2-27. Am J Hum Genet 1997; 60: 588-596.
49. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, Gonzalez-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW: Hereditary earlyonset Parkinson's disease caused by mutations in PINK1. Science 2004; 304: 1158- 1160.
50. Valente EM, Bentivoglio AR, Dixon PH, Ferraris A, Ialongo T, Frontali M, Albanese A, Wood NW: Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35- p36. Am J Hum Genet 2001; 68: 895-900.
51. Valente EM, Brancati F, Ferraris A, Graham EA, Davis MB, Breteler MM, Gasser T, Bonifati V, Bentivoglio AR, De Michele G, Durr A, Cortelli P, Wassilowsky D, Harhangi BS, Rawal N, Caputo V, Filla A, Meco G, Oostra BA, Brice A, Albanese A, Dallapiccola B, Wood NW: PARK6-linked parkinsonism occurs in several European families. Ann Neurol 2002; 51: 14-18.
52. Deng H, Dodson MW, Huang H, Guo M: The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in drosophila. Proc Natl Acad Sci USA 2008; 105: 14503-14508.
53. Poole AC, Thomas RE, Andrews LA, Mc- Bride HM, Whitworth AJ, Pallanck LJ: The PINK1/Parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci USA 2008; 105: 1638-1643.
54. Kuhn K, Zhu XR, Lubbert H, Stichel CC: Parkin expression in the developing mouse. Brain Res Dev Brain Res 2004; 149: 131-142.
55. Unoki M, Nakamura Y: Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene2001; 20: 4457-4465.
56. Vives-Bauza C, de Vries RL, Tocilescu M, Przedborski S: PINK1/Parkin direct mitochondria to autophagy. Autophagy 2010; 6: 315-316.
57. Anichtchik O, Diekmann H, Fleming A, Roach A, Goldsmith P, Rubinsztein DC: Loss of PINK1 function affects development and results in neurodegeneration in zebrafish. J Neurosci 2008; 28: 8199-8207.
58. Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N, Yang Y, Fecto F, Shi Y, Zhai H, Jiang H, Hirano M, Rampersaud E, Jansen GH, Donkervoort S, Bigio EH, Brooks BR, Ajroud K, Sufit RL, Haines JL, Mugnaini E, Pericak-Vance MA, Siddique T: Mutations in UBQLN2 cause dominant Xlinked juvenile and adult-onset ALS and ALS/dementia. Nature 2011; 477: 211-215.
59. Thomas KJ, McCoy MK, Blackinton J, Beilina A, van der Brug M, Sandebring A, Miller D, Maric D, Cedazo-Minguez A, Cookson MR: DJ-1 acts in parallel to the PINK1/ Parkin pathway to control mitochondrial function and autophagy. Hum Mol Genet 2011; 20: 40-50.
60. Stanwood GD, Levitt P: Prenatal exposure to cocaine produces unique developmental and long-term adaptive changes in dopamine D 1 receptor activity and subcellular distribution. J Neurosci 2007; 27: 152-157.
61. Powell EM, Campbell DB, Stanwood GD, Davis C, Noebels JL, Levitt P: Genetic disruption of cortical interneuron development causes region- and GABA cell type-specific deficits, epilepsy, and behavioral dysfunction. J Neurosci 2003; 23: 622-631.
62. Svitkina T, Lin W-H, Webb DJ, Yasuda R, Wayman GA, Van Aelst L, Soderling SH: Regulation of the postsynaptic cytoskeleton:roles in development, plasticity, and disorders. J Neurosci 2010; 30: 14937-14942.
63. Jin SM, Lazarou M, Wang C, Kane LA, Narendra DP, Youle RJ: Mitochondrial membrane potential regulates PINK1 import andproteolytic destabilization by PARL. J Cell Biol 2010; 191: 933-942.
64. Matsuda N, Sato S, Shiba K, Okatsu K, Saisho K, Gautier CA, Sou YS, Saiki S, Kawajiri S,Sato F, Kimura M, Komatsu M, Hattori N, Tanaka K: PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent parkin for mitophagy. J Cell Biol 2010; 189: 211-221.
65. Meissner C, Lorenz H, Weihofen A, Selkoe DJ, Lemberg MK: The mitochondrial intramembrane protease PARL cleaves human pink1 to regulate PINK1 trafficking. J Neurochem 2011; 117: 856-867.
66. Lin W, Kang UJ: Characterization of PINK1 processing, stability, and subcellular localization. J Neurochem 2008; 106: 464-474.
67. Chan NC, Salazar AM, Pham AH, Sweredoski MJ, Kolawa NJ, Graham RL, Hess S, Chan DC: Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy. Hum Mol Genet 2011; 20: 1726- 1737.
68. Gao HM, Hong JS: Gene-environment interactions: key to unraveling the mystery of Parkinson's disease. Prog Neurobiol 2011; 94: 1-19.
69. Langston JW, Ballard P, Tetrud JW, Irwin I:Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979-980.
70. Bertollini R, Danzon M: A dialogue onchemicals and children. Bull World Health Organ 2004; 82:814.
71. Centers for Disease Control and Prevention: Fourth National Report on Human Exposure to Environmental Chemicals. 2009, pp 1-11.